Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $467 from $435 and keeps an Equal Weight rating on the shares. The ...

Reports Q4 revenue $2.91B, consensus $2.78B. “2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another ...

Inside the Operations That Took Captive 2 North Korean Soldiers Fighting Ukraine Experts reveal the seven odd behaviors ...

The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...

Some citizens and archaeologists are concerned about what they see as widespread "mismanagement" of Egypt's rich cultural ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Setting aside a rather brief hiccup mid-quarter, the bull market in global equities continued in force during Q4 2024. Click here to read the full commentary.

After hours: February 7 at 7:59:30 PM EST Loading Chart for VRTX ...